Port de Sagunt | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, proteinuria, systemic lupus erythematosus, urinary system disorder	Recruiting	Phase 2	2026-10-01		NCT05268289
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, complement 3 glomerulopathy, proteinuria, urinary system disorder	Recruiting	Phase 3	2026-07-13		NCT04817618
Atrasentan in Patients With Proteinuric Glomerular Diseases	Alport syndrome, Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Abnormalities, Urogenital Diseases, autoimmune disease, connective tissue disorder, diabetes mellitus, diabetic kidney disease, endocrine system disorder, focal segmental glomerulosclerosis, glomerulonephritis, hereditary nephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder	Active, not recruiting	Phase 2	2026-06-01		NCT04573920